Neoadjuvant Sequential Therapy in Locally Advanced Mid/Low Rectal Cancer

• Status: Unknown status
• Trial end date: 2018-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Compared curative effect，safety and compliance between concurrent chemoradiotherapy and chemo-chemoradio-chemo sequential therapy in locally advanced mid/low rectal cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Harbin Medical University
• Treatments: Capecitabine

Criteria

Inclusion Criteria:

• Pathology rectal adenocarcinoma

• Distal distance of tumor from anal verge < 10cm

• TNM staging T3-4N0-2(MRI)

• No distant metastasis

• Karnofsky score≥70

• Female patients need contraception during the test

• Postmenopausal women for at least 12 months, expect pregnancy possibility

• Patients did not receive chemotherapy, radiotherapy in any form before

• No other severe related diseases (such as other tumor, severe cardiac and central nervous system diseases, etc.)

Exclusion Criteria:

• Be treated by radiotherapy, chemotherapy or tumor biological therapy before

• Received immunosuppressive therapy (including corticosteroids)

• Participated in other clinical trial(s) in 1 month

• With malignant tumor of colon

• Peripheral neuropathy (WHO I level and above)

• Neurological or psychiatric abnormalities affecting cognition , including central nervous system metastasis

• Severe allergies or allergic history

• Severe pulmonary or heart disease

• Pregnant or lactation or refuse contraception during the test

• Suffering other malignant tumors in past